ow.ly/7g3B5100Nms
ow.ly/7g3B5100Nms
Get live updates and key takeaways on emerging ADCs from Anne Chiang and Haifeng Liu #OncTwitter #MedEd #MedX #LungCancer #Oncology
Get live updates and key takeaways on emerging ADCs from Anne Chiang and Haifeng Liu #OncTwitter #MedEd #MedX #LungCancer #Oncology
The US bridging study ASTRIDE reported numerically longer overall survival with serplulimab plus chemotherapy versus atezolizumab plus chemotherapy in ES-SCLC.
📊 Median OS: 12.4 vs 10.2 months
Presented by David Gandara
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
The US bridging study ASTRIDE reported numerically longer overall survival with serplulimab plus chemotherapy versus atezolizumab plus chemotherapy in ES-SCLC.
📊 Median OS: 12.4 vs 10.2 months
Presented by David Gandara
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
Extended follow-up from the phase 3 DeLLphi-304 trial showed durable survival benefit with tarlatamab in previously treated #SCLC.
📊 Median OS: 13.6 vs 8.4 months
📊 38% lower risk of death
Presented by @charlesrudin.bsky.social
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedSky
Extended follow-up from the phase 3 DeLLphi-304 trial showed durable survival benefit with tarlatamab in previously treated #SCLC.
📊 Median OS: 13.6 vs 8.4 months
📊 38% lower risk of death
Presented by @charlesrudin.bsky.social
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedSky
Updated DeLLphi-304 data also showed sustained long-term benefit with tarlatamab in previously treated #SCLC.
📊 2-year OS: 30% vs 15%
📊 Sustained disease control ≥52 weeks: 24% vs 4%
No new safety signals.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky
Updated DeLLphi-304 data also showed sustained long-term benefit with tarlatamab in previously treated #SCLC.
📊 2-year OS: 30% vs 15%
📊 Sustained disease control ≥52 weeks: 24% vs 4%
No new safety signals.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky
ASTRIDE provided US data supporting serplulimab in ES-SCLC, with outcomes consistent with the phase 3 ASTRUM-005 trial.
📊 2-year OS: 32.2% vs 17.6% 📊 Median PFS: 5.4 vs 4.9 months
No new safety signals identified.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
ASTRIDE provided US data supporting serplulimab in ES-SCLC, with outcomes consistent with the phase 3 ASTRUM-005 trial.
📊 2-year OS: 32.2% vs 17.6% 📊 Median PFS: 5.4 vs 4.9 months
No new safety signals identified.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
Phase 1 data for SKB500, a B7-H3-targeted ADC, also demonstrated encouraging activity in heavily pretreated ES-SCLC.
📊 ORR: 62.5%-66.7%
📊 Median PFS: 5.6-8.1 months
Presented by Haifeng Liu.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedSky
Phase 1 data for SKB500, a B7-H3-targeted ADC, also demonstrated encouraging activity in heavily pretreated ES-SCLC.
📊 ORR: 62.5%-66.7%
📊 Median PFS: 5.6-8.1 months
Presented by Haifeng Liu.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedSky
New data for ABBV-706, a first-in-class SEZ6-targeted ADC, showed promising activity in relapsed/refractory #SCLC.
📊 ORR: 56% at the recommended phase 3 dose
📊 Median OS: 12.4 months
Presented by Anne Chiang
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedSky
New data for ABBV-706, a first-in-class SEZ6-targeted ADC, showed promising activity in relapsed/refractory #SCLC.
📊 ORR: 56% at the recommended phase 3 dose
📊 Median OS: 12.4 months
Presented by Anne Chiang
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedSky
More from Krascendo-1:
📊 Confirmed ORR: 58% with divarasib vs 32% with sotorasib/adagrasib
📉 Grade 3–4 TRAEs: 24.6% vs 34.5%
📉 TRAE discontinuations: 4.8% vs 11.7%
No emergent new safety signals
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky
More from Krascendo-1:
📊 Confirmed ORR: 58% with divarasib vs 32% with sotorasib/adagrasib
📉 Grade 3–4 TRAEs: 24.6% vs 34.5%
📉 TRAE discontinuations: 4.8% vs 11.7%
No emergent new safety signals
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky
Post-hoc 2L analysis of SigVie-002: Favorable trends with sigvotatug vedotin vs docetaxel:
📊 OS: 13.6 vs 11.1 mo
📊 PFS: 5.9 vs 4.2 mo
No clear relationship with high IB6 expression
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky @solangepeters.bsky.social
Post-hoc 2L analysis of SigVie-002: Favorable trends with sigvotatug vedotin vs docetaxel:
📊 OS: 13.6 vs 11.1 mo
📊 PFS: 5.9 vs 4.2 mo
No clear relationship with high IB6 expression
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky @solangepeters.bsky.social
SAFFRON: osimertinib + savolitinib significantly improved OS & PFS vs platinum-pemetrexed in EGFRmut, MET-driven adv #NSCLC after osimertinib
Speaker: Shun Lu
📊 PFS: 7.6 vs 5.4 months; HR 0.55
📊 OS: 17.8 vs 12.9 months; HR 0.68
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
SAFFRON: osimertinib + savolitinib significantly improved OS & PFS vs platinum-pemetrexed in EGFRmut, MET-driven adv #NSCLC after osimertinib
Speaker: Shun Lu
📊 PFS: 7.6 vs 5.4 months; HR 0.55
📊 OS: 17.8 vs 12.9 months; HR 0.68
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
📊 DoR: 9.7 vs 5.7 months
📊 Grade ≥3 TEAEs: 64% vs 63%
📊 TEAE discontinuation (all cause): 14% vs 8%
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky
📊 DoR: 9.7 vs 5.7 months
📊 Grade ≥3 TEAEs: 64% vs 63%
📊 TEAE discontinuation (all cause): 14% vs 8%
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky
Krascendo-1: divarasib significantly improved PFS and OS vs sotorasib/adagrasib in previously treated KRAS G12C-mutated #NSCLC
📊 PFS: 9.8 vs 5.7 months; HR 0.58
📊 OS: 17.7 vs 12.0 months; HR 0.56
Presented by Ferdinandos Skoulidis
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
Krascendo-1: divarasib significantly improved PFS and OS vs sotorasib/adagrasib in previously treated KRAS G12C-mutated #NSCLC
📊 PFS: 9.8 vs 5.7 months; HR 0.58
📊 OS: 17.7 vs 12.0 months; HR 0.56
Presented by Ferdinandos Skoulidis
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
SigVie-002 study: sigvotatug vedotin did not significantly improve OS vs docetaxel in previously treated nonsquamous #NSCLC.
📊 Median OS: 11.9 vs 11.5 months
📊 HR 0.929; P=0.226
Presented by @solangepeters.bsky.social
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
SigVie-002 study: sigvotatug vedotin did not significantly improve OS vs docetaxel in previously treated nonsquamous #NSCLC.
📊 Median OS: 11.9 vs 11.5 months
📊 HR 0.929; P=0.226
Presented by @solangepeters.bsky.social
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
OptiTROP-Lung06: sac-TMT + pembrolizumab significantly improved PFS vs chemo + pembrolizumab in 1L PD-L1-negative advanced nonsquamous #NSCLC
📊 Median PFS: 15.0 vs 5.7 months
📉 HR 0.49; P<0.0001
Presented by Caicun Zhou
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
OptiTROP-Lung06: sac-TMT + pembrolizumab significantly improved PFS vs chemo + pembrolizumab in 1L PD-L1-negative advanced nonsquamous #NSCLC
📊 Median PFS: 15.0 vs 5.7 months
📉 HR 0.49; P<0.0001
Presented by Caicun Zhou
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
At 32.3 months' follow-up in OptiTROP-Lung04:
📊 24-month OS: 54.1% vs 37.2%
📊 30-month OS: 40.5% vs 28.4%
No new safety signals emerged with extended follow-up of sac-TMT vs chemotherapy.
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky
At 32.3 months' follow-up in OptiTROP-Lung04:
📊 24-month OS: 54.1% vs 37.2%
📊 30-month OS: 40.5% vs 28.4%
No new safety signals emerged with extended follow-up of sac-TMT vs chemotherapy.
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky
More from OptiTROP-Lung06:
📊 ORR: 50.2% vs 47.3%
📊 DoR: 13.6 vs 6.8 months
📉 Grade ≥3 TEAEs: 47.6% vs 60.6%
OS data remain immature, with a favorable trend for sac-TMT + pembrolizumab (HR 0.58).
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky
More from OptiTROP-Lung06:
📊 ORR: 50.2% vs 47.3%
📊 DoR: 13.6 vs 6.8 months
📉 Grade ≥3 TEAEs: 47.6% vs 60.6%
OS data remain immature, with a favorable trend for sac-TMT + pembrolizumab (HR 0.58).
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky
A post-hoc 2L analysis of LBA68 showed favorable trends with sigvotatug vedotin vs docetaxel:
📊 OS: 13.6 vs 11.1 months
📊 PFS: 5.9 vs 4.2 months
Similar trends were not observed in the 3L+ subgroup
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky @solangepeters.bsky.social
A post-hoc 2L analysis of LBA68 showed favorable trends with sigvotatug vedotin vs docetaxel:
📊 OS: 13.6 vs 11.1 months
📊 PFS: 5.9 vs 4.2 months
Similar trends were not observed in the 3L+ subgroup
#LungCancer #NSCLC #Oncology #OncTwitter #MedEd #MedSky @solangepeters.bsky.social
Final OS analysis of OptiTROP-Lung04: sac-TMT maintained an OS benefit vs platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated #NSCLC
📊 Median OS: 25.9 vs 17.4 months
📉 HR 0.69
Presented by Wen Feng Fang
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
Final OS analysis of OptiTROP-Lung04: sac-TMT maintained an OS benefit vs platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated #NSCLC
📊 Median OS: 25.9 vs 17.4 months
📉 HR 0.69
Presented by Wen Feng Fang
#LungCancer #Oncology #OncTwitter #MedEd #MedSky
#LungCancer #Oncology #SCLC #OncTwitter #MedEd #MedX
#LungCancer #Oncology #SCLC #OncTwitter #MedEd #MedX
DeLLphi-305: Tarlatamab + durvalumab significantly improved OS vs durvalumab alone as 1LM therapy for ES-SCLC.
📊 Median OS: 21.1 vs 12.7 months
📉 Risk of death reduced by 58%
Presented by
Jacob Sands
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
DeLLphi-305: Tarlatamab + durvalumab significantly improved OS vs durvalumab alone as 1LM therapy for ES-SCLC.
📊 Median OS: 21.1 vs 12.7 months
📉 Risk of death reduced by 58%
Presented by
Jacob Sands
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
Further DeLLphi-305 results favored tarlatamab + durvalumab vs durvalumab alone in 1LM ES-SCLC
📊 Median PFS: 7.4 vs 1.9 months
📊 ORR: 26.4% vs 4.1%
CRS was predominantly low grade; no fatal CRS or ICANS events
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky
Further DeLLphi-305 results favored tarlatamab + durvalumab vs durvalumab alone in 1LM ES-SCLC
📊 Median PFS: 7.4 vs 1.9 months
📊 ORR: 26.4% vs 4.1%
CRS was predominantly low grade; no fatal CRS or ICANS events
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky
Swipe to see the answers and explanations!
#Engasertib #AKTInhibitor #AKTPathway #BreastCancer #Oncology #CancerResearch #ClinicalTrials #Phase1Trial #NEJM #MedicalEducation #OncologyEducation #MedEd #CancerCare #AdverseEvents #OncTwitter #HemeOnc #HEMEHUB
Swipe to see the answers and explanations!
#Engasertib #AKTInhibitor #AKTPathway #BreastCancer #Oncology #CancerResearch #ClinicalTrials #Phase1Trial #NEJM #MedicalEducation #OncologyEducation #MedEd #CancerCare #AdverseEvents #OncTwitter #HemeOnc #HEMEHUB